garenoxacin

Garenoxacin is a broad-spectrum quinolone antibiotic developed for the treatment of Gram-positive and Gram-negative bacterial infections. It acts by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination. This inhibition leads to disruption of bacterial cell division and ultimately cell death. Garenoxacin is notable as a des-F(6)-quinolone (lacking a fluorine at the C-6 position), yet retains potent activity against a wide range of pathogens including multidrug-resistant *Streptococcus pneumoniae*, β-lactamase-producing *Moraxella catarrhalis*, ampicillin-resistant *Haemophilus influenzae* (BLNAR), *Chlamydia spp.*, *Mycoplasma pneumoniae*, and *Legionella spp.* The drug was discovered by Toyama Chemical in Japan and marketed there under the brand name Geninax; Schering-Plough held rights outside Japan but withdrew regulatory applications in both the US and Europe after review[1][3][7][8].

Brand names

Geninax

Other names

ganefloxacingarenfloxacin